City Clinical Hospital # 40
About City Clinical Hospital # 40
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Janssen Research & Development, LLC
4
Celgene
3
Hoffmann-La Roche
2
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
1
Institut de Recherches Internationales Servier
1
Janssen-Cilag Ltd.
1
Millennium Pharmaceuticals, Inc.
1
Pfizer
1
Sandoz
1
Supergene, LLC
1
Takeda
1
Clinical Trials at City Clinical Hospital # 40
During the past decade, City Clinical Hospital # 40 conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 8 clinical trials were completed, i.e. on
average, 61.5% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 7 clinical trials were completed. i.e. 700%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
2007-09-01
2010-01-01
Terminated
337
Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis
2009-06-18
2011-02-18
Completed
195
A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.
2009-10-31
2011-02-14
Completed
201
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
2009-10-31
2014-01-28
Completed
1,162
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
2015-12-30
2023-12-31
Active, not recruiting
319
Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
2017-02-14
2021-10-05
Completed
34
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
2017-08-01
2021-11-26
Completed
122
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
2017-06-26
2024-06-30
Active, not recruiting
146
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "City Clinical Hospital # 40" #1 sponsor was "Janssen Research & Development, LLC" with 4 trials, followed by "Celgene" with 3 trials
sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Federal Research Institute of Pediatric Hematology, Oncology and Immunology" with 1 trials sponsored and "Institut de Recherches Internationales Servier"
with 1 trials sponsored. Other sponsors include 1 different institutions and
companies that sponsored additional 11 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "City Clinical Hospital # 40"
#1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation" with 1 trials as a collaborator, "Legend Biotech" with 1 trials as a collaborator, "Takeda Development Center Americas, Inc." with 1 trials as a collaborator and "argenx" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at City Clinical Hospital # 40
According to Clinical.Site data, the most researched conditions in "City Clinical Hospital # 40" are
"Leukemia, Myeloid, Acute" (3 trials), "Rheumatoid Arthritis" (3 trials), "Multiple Myeloma" (2 trials), "Myelodysplastic Syndromes" (2 trials) and "AML Arising From Myelodysplastic Syndrome (MDS)" (1 trials). Many other conditions were trialed in "City Clinical Hospital # 40" in a lesser frequency.
Clinical Trials Intervention Types at City Clinical Hospital # 40
Most popular intervention types in "City Clinical Hospital # 40" are "Drug" (16 trials) and "Other" (3 trials). Other intervention types were less common.
The name of intervention was led by "Azacitidine" (4 trials), "Placebo" (2 trials), "AG-120" (1 trials), "AG-221" (1 trials) and "Alteplase" (1 trials). Other intervention names were less common.
Clinical Trials Genders at City Clinical Hospital # 40
The vast majority of trials in "City Clinical Hospital # 40" are
17 trials for "All" genders.
Clinical Trials Status at City Clinical Hospital # 40
Currently, there are NaN active trials in "City Clinical Hospital # 40".
undefined are not yet recruiting,
2 are recruiting,
8 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 6 completed trials in City Clinical Hospital # 40,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in City Clinical Hospital # 40, 0 "Phase 1"
clinical trials were conducted, 5 "Phase 2" clinical
trials and 10 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".